Intervacc AB (publ), a Swedish growth company specialising in animal vaccines, highlights the annual initiative Strangles Awareness Week – an international awareness campaign aimed at reducing the spread of strangles ... Read more
Today, Intervacc AB (publ), a Swedish growth company specialising in animal vaccines, together with Dechra Pharmaceuticals PLC, is hosting a European Key Opinion Leader (KOL) meeting focused on advancing best practice ... Read more
Intervacc AB (publ) announces that Strangvac®, the company’s innovative vaccine against strangles in horses, has been approved by the authorities in Iceland.
Strangles, a ... Read more
Intervacc AB (publ) announces that the company's 2025 Annual Report has been published today. The annual report (in Swedish) is attached and an English unaudited translation of the report is available for download on ... Read more
The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Annual General Meeting (“AGM”) to be held on Wednesday 13 May 2026 at 3.00 p.m. at Cirio Advokatbyrå, ... Read more